MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Lysosomal disorders"

  • 2025 International Congress

    Neurological manifestations and genotypes of Gaucher disease type 3: MDSGene systematic review

    S. Schaake, T. Usnich, J. Boehm, N. Steffen, N. Schell, C. Krüger, T. Gül-Demirkale, N. Bahr, T. Kleinz, H. Madoev, B. Laabs, Z. Gan-Or, R. Alcalay, C. Marras, K. Lohmann, C. Klein, M. Rossi (Luebeck, Germany)

    Objective: To characterize the spectrum of neurological manifestations of Gaucher disease type 3 (GD3) and identify the most common GBA1 variants. Background: Gaucher disease is…
  • 2025 International Congress

    Modifiers of Parkinson’s disease associated with mutations in the GBA1 gene based on transcriptome data validation

    A. Bezrukova, K. Basharova, I. Miliukhina, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: To identify modifiers of Parkinson's disease (PD) among carriers of mutations in the GBA1 gene based on transcriptome data validation analysis by the assessing…
  • 2025 International Congress

    Oligodendrocyte-specific mRNA therapy with lipid nanoparticles

    M. Sawamura, K. Tachikawa, R. Hikawa, H. Yamakado, R. Takahashi, S. Matsuzawa (San Diego, USA)

    Objective: To develop lipid nanoparticles with high efficiency and specificity to introduce mRNA into oligodendrocytes. To denmonstrate the potential therapy of Krabbe disease as one…
  • 2025 International Congress

    G-Can, the GBA1 Canada Initiative

    L. Chebon, P. Halder, E. Fon, T. Durcan, M. Parent, N. Dupre, M. Sharp, R. Postuma, G. Armstrong, A. Milnerwood, A. Dagher, J. Raamsdonk, J. Trempe, T. Goldsmith, X. Chen, N. Aprahamian, Z. You, M. Nicoleau, E. Deneault, A. Bayne, C. Laflamme, P. Mcpherson, M. Pandolfo, G. Rouleau, Z. Gan-Or (Québec, Canada)

    Objective: G-Can, the GBA1 Canada Initiative, is an open-science platform which aims to advance GBA1 research and develop treatments for GBA1 mutation-related Parkinson's disease (PD).…
  • 2025 International Congress

    Investigating the cellular consequences of the G2385R LRRK2 variant

    P. Lewis, S. Herbst (London, United Kingdom)

    Objective: The objective of this study is to characterise the biochemical and cellular impact of the G2385R coding variant in LRRK2, a risk variant for…
  • 2025 International Congress

    CSM-101 is a Small Molecule Agonist of TRPML1 for Parkinson’s-Related Disorders

    L. Murphy, J. Fortanet, D. Baird, T. Lehmberg, K. Skerry, M. Broadus (Boston, USA)

    Objective: (i) To develop a brain-penetrant small molecule agonist for the lysosomal TRPML1 channel and, (ii) Perform preclinical studies supporting development in Parkinson’s-related disorders. Background:…
  • 2025 International Congress

    VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease

    M. Facheris, D. Ysselstein, J. van Dervalk, E. Thijssen, L. Pagan, G. Valstar, C. Schotborgh, P. Kremer, M. Hagey, J. Cederbaum, J. Sullivan, K. Hunt, O. Siddiqui (Chicago, USA)

    Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VQ-101 in healthy volunteers (HVs), and individuals with Parkinson’s disease (PD) with and without GBA1…
  • 2024 International Congress

    Interaction of GCase and ganglioside GM1 in the aggregation of α-Synuclein

    F. Fierli, G. Uras, S. Lucas-Del Pozo, S. Koletsi, V. Lentini, M. Toffoli, P. Caboni, A. Schapira (London, United Kingdom)

    Objective: The objective of this work is to investigate the relationship between ganglioside GM1 levels and α-synuclein aggregation in the context of GBA1 mutations. Background:…
  • 2024 International Congress

    Bi-allelic BORCS5 Variants Result In A Wide Spectrum of Progressive Neurodevelopmental Disorders via Lysosomal Dysfunction

    NE. Mencacci, G. Minakaki, R. Maroofian, R. de Pace, F. Magrinelli, S. Eldessouky, WJ. Peng, B. Doan, J. Baptista, T. Marton, J. Vogt, JD. Ortigoza-Escobar, L. Martorell, EJ. Kamsteeg, A. Mahmoud, A. Scardamaglia, MS. Zaki, G. Zifarelli, Z. Alhassnan, NW. Wood, M. Schwake, J. Bonifacino, H. Houlden, KP. Bhatia, D. Krainc (Chicago, USA)

    Objective: To characterize a new brain disorder associated with BORCS5 variants, elucidating their effect on lysosomal distribution and activity Background: BORCS5 encodes a subunit of…
  • 2024 International Congress

    Prevalence of Parkinson’s Disease and Possible Parkinsonian Syndrome in Gaucher Disease: Data From the ICGG Gaucher Registry

    R. Alcalay, P. Mistry, A. Di Fonzo, J. Batista, P. Bianculli, J. Carwile, G. Perichon, M. Balwani (New York, USA)

    Objective: To estimate the age-specific risk of Parkinson’s disease (PD) and possible parkinsonian syndrome (pPS) in Gaucher disease (GD) based on registry data. Background: While…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 9
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #29077 (not found)
  • #29056 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28189 (not found)
  • Welcome to the MDS Abstracts Site
  • Advanced Search
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley